Prevail Therapeutics

About:

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.

Website: https://www.prevailtherapeutics.com/

Top Investors: Alexandria Venture Investments, RA Capital Management, AbbVie, OrbiMed, Biotechnology Value Fund

Description:

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.

Total Funding Amount:

$129M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)prevailtherapeutics.com

Founders:

Asa Abeliovich

Number of Employees:

51-100

Last Funding Date:

2019-03-27

IPO Status:

Public

Industries:

© 2025 bioDAO.ai